share_log

BRIEF-Agios Submits Supplemental New Drug Application To FDA For Tibsovo (Ivosidenib Tablets) For Patients With Previously Trea

BRIEF-Agios Submits Supplemental New Drug Application To FDA For Tibsovo (Ivosidenib Tablets) For Patients With Previously Trea

Brief-Agios向FDA提交针对Tibsovo(Ivosidenib片)的补充新药申请，用于既往治疗的患者
路透社 ·  2021/03/01 22:09

March 1 (Reuters) - Agios Pharmaceuticals Inc :
   * AGIOS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA FOR TIBSOVO® (IVOSIDENIB TABLETS) FOR PATIENTS WITH PREVIOUSLY TREATED IDH1-MUTANT CHOLANGIOCARCINOMA
   * AGIOS PHARMACEUTICALS - CO HAS REQUESTED PRIORITY REVIEW FOR APPLICATION OF TIBSOVO, WHICH, IF GRANTED, COULD RESULT IN A SIX-MONTH REVIEW PROCESS

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)

路透3月1日电-Agios PharmPharmticals Inc：*Agios向FDA提交TIBSOVO®(IVOSIDENIB片剂)的补充新药申请，用于先前治疗的IDH1突变胆管癌患者*Agios PharmPharmticals-CO已要求优先审查TIBSOVO的申请，如果获得批准，可能需要6个月的审查过程Eikon的源文本：进一步的公司报道：(Reurs.Briefs@thomsonreurs.com；)

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发